All Videos

Neal Bhatia, MD, outlines the clinical rationale for incorporating photodynamic therapy into skin cancer treatment algorithms, from field cancerization management to emerging applications in superficial basal cell carcinoma.

Microbiome-first biotech in dermatology is shifting from harsh acne treatments to balance-focused solutions, using anti-inflammatory compounds that support healthier skin ecosystems.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Maryanne Makredes Senna, MD, shares why mineral sunscreens matter for patients with frontal fibrosing alopecia, and why reprimanding sun-seekers may be more detrimental to patient care.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

In this first episode, Elizabeth Buzney, MD, explains why EPP patients suffer for years before receiving an accurate diagnosis, and what clinicians need to know about this debilitating rare disease.

Rajani Katta, MD, and Renata Block, DMSCc, MMS, PA-C, explore how gut microbes, fiber, and fermented foods could shape eczema, acne, and rosacea—and why probiotics aren’t one-size-fits-all.

Neal Bhatia, MD, explains why photodynamic therapy's ability to target subclinical damage across the entire field makes it one of dermatology's most powerful chemopreventive tools.

Maryanne Makredes Senna, MD, discusses emerging data suggesting extended-release oral minoxidil tablets may improve efficacy while minimizing cardiovascular adverse effects in patients with androgenetic alopecia.

Neal Bhatia, MD, makes the case for photodynamic therapy as a versatile, field-treating option, not just an alternative to surgery.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Once-daily roflumilast cream brings fast itch relief, EASI-75 responses, and reassuring safety in 3–24 months, supporting a recent sNDA to the FDA.

Daniel Condie, MD, shares kid-friendly sun safety tips, tanning bed warnings, and early skin cancer detection advice that clinicians can share with families and teens.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Daniel Condie, MD, debunks common Gen Z tanning myths, warns base tans and sunscreen fears fuel early skin cancer, and explains Mohs care challenges.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress, including laughter yoga, relationships, and mindset shifts

At the 2026 AAD Annual Meeting, dermatologists shared their go-to strategies for managing stress — from family time and fitness to emotional intelligence training and even Botox.

Allergist and bestselling author Zachary Rubin, MD, joins host Renata Block, DMSc, MMS, PA-C, to debunk common allergy and atopic dermatitis myths and explore the immunology of the atopic march, cross-specialty collaboration, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

Many participants in the mobile screening program have never previously seen a dermatologist.

Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.

GLP-1 agonists may aid psoriasis, wound healing, and cardiometabolic health—Daniel Walker, MD, FAAD, explains why dermatologists should start to pay attention.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

April Armstrong, MD, MPH, discusses the role of itch as a key driver of psoriasis burden and shows how next-generation oral TYK2 inhibitors like envudeucitinib provide rapid symptom relief and meaningful improvements in quality of life.

April Armstrong, MD, MPH, highlights envudeucitinib as a next-generation oral TYK2 inhibitor that delivers biologic-level efficacy and strong safety, expanding treatment options for patients with moderate to severe psoriasis.

April Armstrong, MD, MPH, reframes psoriasis as a systemic inflammatory disease and highlights a shift toward earlier systemic treatment, with emerging oral therapies like TYK2 inhibitors offering improved efficacy and safety.